Triune Financial Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$606K Buy
524
+9
+2% +$10.6K 0.12% 25
2026
Q2
$617K Buy
515
+7
+1% +$7.15K 0.13% 22
2026
Q1
$467K Hold
508
– – 0.11% 27
2025
Q4
$527K Hold
508
– – 0.12% 25
2025
Q3
$387K Hold
508
– – 0.1% 27
2025
Q2
$396K Sell
508
-160
-24% -$124K 0.11% 24
2025
Q1
$552K Buy
668
+35
+6% +$29.1K 0.18% 16
2024
Q4
$489K Hold
633
– – 0.15% 17
2024
Q3
$561K Hold
633
– – 0.18% 14
2024
Q2
$573K Sell
633
-1
-0.2% -$800 0.2% 13
2024
Q1
$493K Sell
634
-17
-3% -$12.1K 0.17% 18
2023
Q4
$380K Sell
651
-237
-27% -$138K 0.14% 20
2023
Q3
$477K Hold
888
– – 0.2% 16
2023
Q2
$417K Buy
+888
New +$372K 0.17% 18

Other funds holding LLY

Triune Financial Partners's LLY Position: Q3 2026 in Review

Triune Financial Partners increased its Eli Lilly (LLY) stake by 1.7% in Q3 2026, buying an estimated $10.6K and bringing the position to 524 shares worth $606K. The position accounts for 0.12% of the portfolio, ranked #25.

Triune Financial Partners first reported a position in LLY in Q2 2023 and has held it in 14 quarters since. The position peaked at $617K in Q2 2026. 3,033 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Triune Financial Partners held 524 shares of Eli Lilly worth $606K as of Q3 2026.
  • Triune Financial Partners bought 9 Eli Lilly shares in Q3 2026, an estimated $10.6K.
  • Eli Lilly made up 0.12% of Triune Financial Partners's portfolio in Q3 2026, its #25 holding.
  • Triune Financial Partners first reported a position in Eli Lilly in Q2 2023 and has held it in 14 quarters since.
  • Triune Financial Partners's Eli Lilly position peaked at $617K in Q2 2026.
  • 3,033 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Triune Financial Partners's 13F filing for Q3 2026, filed 3 Nov 2026.